Stay updated on Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page.

Latest updates to the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page
- Check2 days agoChange DetectedThe page’s footer “Revision” version was updated from v3.5.2 to v3.5.3, reflecting a backend/site release rather than a change to the study record content.SummaryDifference0.1%

- Check9 days agoChange DetectedRevision: v3.5.2 updated from v3.5.0. No visible changes to study details or page content.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check24 days agoChange DetectedAdded the keyword/MeSH term 'B-cell chronic lymphocytic leukemia.' Added a new resource link to the Genetic and Rare Diseases Information Center.SummaryDifference0.2%

- Check38 days agoChange DetectedRevision tag updated to v3.5.0, replacing v3.4.3. This is a UI/version change and does not alter study details or eligibility.SummaryDifference0.1%

- Check46 days agoChange DetectedFooter revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check53 days agoChange DetectedUpdates to the study record dates show new entries on 2026-03-02, 2026-02-26, and 2026-02 and removal of entries on 2025-12-24, 2025-12-08, and 2025-12, indicating revisions to the trial information.SummaryDifference0.2%

Stay in the know with updates to Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page.